- Home
- GLQ vs ADCT Comparison
GLQ vs ADCT Comparison
Compare GLQ & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLQ
- ADCT
- Stock Information
- Founded
- GLQ 2005
- ADCT 2011
- Country
- GLQ United States
- ADCT Switzerland
- Employees
- GLQ N/A
- ADCT N/A
- Industry
- GLQ Finance/Investors Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- GLQ Finance
- ADCT Health Care
- Exchange
- GLQ Nasdaq
- ADCT Nasdaq
- Market Cap
- GLQ 119.5M
- ADCT 143.1M
- IPO Year
- GLQ N/A
- ADCT 2020
- Fundamental
- Price
- GLQ $6.27
- ADCT $1.41
- Analyst Decision
- GLQ
- ADCT Strong Buy
- Analyst Count
- GLQ 0
- ADCT 5
- Target Price
- GLQ N/A
- ADCT $7.75
- AVG Volume (30 Days)
- GLQ 65.5K
- ADCT 345.0K
- Earning Date
- GLQ 01-01-0001
- ADCT 03-27-2025
- Dividend Yield
- GLQ 11.11%
- ADCT N/A
- EPS Growth
- GLQ N/A
- ADCT N/A
- EPS
- GLQ N/A
- ADCT N/A
- Revenue
- GLQ N/A
- ADCT $70,837,000.00
- Revenue This Year
- GLQ N/A
- ADCT $11.56
- Revenue Next Year
- GLQ N/A
- ADCT $17.03
- P/E Ratio
- GLQ N/A
- ADCT N/A
- Revenue Growth
- GLQ N/A
- ADCT 1.84
- 52 Week Low
- GLQ $5.13
- ADCT $1.28
- 52 Week High
- GLQ $6.54
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- GLQ 34.19
- ADCT 36.11
- Support Level
- GLQ $6.38
- ADCT $1.41
- Resistance Level
- GLQ $6.53
- ADCT $1.68
- Average True Range (ATR)
- GLQ 0.08
- ADCT 0.12
- MACD
- GLQ 0.00
- ADCT -0.04
- Stochastic Oscillator
- GLQ 17.19
- ADCT 20.32
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.